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In a prospective, population-based cohort study and a study of primary-healthcare consultations, we had a rare opportunity to es-
timate age-speciﬁc rates of norovirus-associated infectious intestinal disease in the United Kingdom. Rates in children aged <5 years
were signiﬁcantly higher than those for other age groups in the community (142.6 cases per 1000 person-years [95% conﬁdence
interval {CI}, 99.8–203.9] vs 37.6 [95% CI, 31.5–44.7]) and those for individuals presenting to primary healthcare (14.4 cases per
1000 person-years [95% CI, 8.5–24.5] vs 1.4 [95% CI, .9–2.0]). Robust incidence estimates are crucial for vaccination policy makers.
This study emphasises the impact of norovirus-associated infectious intestinal disease, especially in children aged <5 years.
Keywords. norovirus; acute gastroenteritis; incidence; vaccination; policy; prevention; pediatric; community; primary health-
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Approximately 17 million cases of infectious intestinal disease
(IID) in the United Kingdom per annum [1] account for at least
11 million people taking time off work and 8 million children
being absent from school because of illness. Norovirus is by far
the most commonly diagnosed cause of IID, resulting in ap-
proximately 3 million cases annually [1, 2] and causing partic-
ular problems in closed and semiclosed communities like
schools, hospitals and nursing homes where the impact on chil-
dren and the elderly can be considerable [3].Currently the main
means of controlling the spread of norovirus are good hand hy-
giene, good environmental cleaning, and exclusion from work
or school until cases are symptom free for 48 hours [4]. As
the prospect of an effective vaccine against norovirus becomes
a reality [5], there is a need for country-speciﬁc illness burden
estimates to inform potential national vaccination programs [6].
However, there is a paucity of incidence estimates from high-
income countries in the peer-reviewed literature, and those
that are available are based on data from the 1990s [7, 8]. Fur-
thermore, signiﬁcant underreporting of norovirus in national
surveillance systems can lead to inaccurate estimates of impact
[1]. Therefore, we performed a secondary analysis of data from
the Second Study of Infectious Intestinal Disease in the Com-
munity (hereafter, the IID2 study) in the United Kingdom,
which comprised a population-based cohort study and a pro-
spective study of presentation to primary healthcare [1, 2],
to generate age-speciﬁc incidence estimates for norovirus-
associated IID burden in the population.
METHODS
The IID2 study methods have been described in full elsewhere [1,
2, 9]. Brieﬂy, the study comprised 2 main components: (1) a pro-
spective population-based cohort study in which healthy people
of all ages were randomly selected from a representative sample of
general practices across the United Kingdom and followed up for
symptoms of IID on a weekly basis for 12 months (cohort study)
and (2) a 12-month prospective study of people consulting a pri-
mary healthcare professional with symptoms of IID whowere en-
rolled on clinical presentation (GP presentation study).
Participants who developed symptoms that fulﬁlled the case def-
inition for IID in either the cohort or the GP presentation studies
were requested to complete a symptom questionnaire and submit a
stool sample for microbiological examination. Cases were deﬁned
as “peoplewith loose stools or clinically signiﬁcant vomiting lasting
less than two weeks, in the absence of a known noninfectious
cause, preceded by a symptom-free period of three weeks. Vomit-
ing was clinically signiﬁcant if it occurred more than once in a
24-hour period and if it incapacitated the case or was accompanied
by other symptoms such as cramps or fever [9, p. 3].” The deﬁni-
tion of vomiting excluded noninfectious causes such as morning
sickness, posseting in infants, and vomiting due to pyloric stenosis.
All the study data were collected during 2008 and 2009.
Microbiologic Methods
Two nucleic acid extracts were prepared from each stool sample
[2]. Each extract was examined for a comprehensive range of
Presented in part: Global Burden of Norovirus and Prospects for Vaccine Development
Meeting, Atlanta, Georgia, February 2015.
Correspondence: S. J. O’Brien, NIHR Health Protection Research Unit in Gastrointestinal
Infections, 2nd Floor, Block F, Waterhouse Buildings, 1-5 Brownlow St, Liverpool L69 3GL, UK
(s.j.obrien@liverpool.ac.uk).
The Journal of Infectious Diseases® 2016;213(S1):S15–8
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society
of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
DOI: 10.1093/infdis/jiv411
Age-Speciﬁc Incidence of Norovirus Infection • JID 2016:213 (Suppl 1) • S15
 at Liverpool U






gastrointestinal pathogens, including norovirus, using real-time/
quantitative reverse transcription–polymerase chain reaction
(RT-PCR). A cycle threshold (CT) value of <30 was used to
deﬁne clinically signiﬁcant norovirus. This cut-off was based on
evidence that a considerable proportion of asymptomatic people
have low viral loads detected using real-time/quantitative RT-
PCR and so it is assumed that, in these circumstances, norovirus
is unlikely to be the cause of the patient’s symptoms [10, 11].
Statistical Methods
Methods for estimating incidence in the IID2 study are described
in detail elsewhere [1]. Brieﬂy, we estimated age-speciﬁc rates in
the community from the cohort study by dividing the number of
PCR-conﬁrmed norovirus IID cases in each age group by the
total number of person-years at risk in that age group. Because
not all IID cases submitted stool specimens for analysis, the
total number of PCR-conﬁrmed norovirus IID cases was derived
from an imputation model that inferred pathogen positivity as a
function of age, sex, and symptom proﬁle. Incidence estimates
were computed as an average from 20 imputed data sets, account-
ing for within- and between-imputation variances in the calcula-
tion of 95% conﬁdence intervals (CIs).
We estimated age-speciﬁc rates of primary healthcare consul-
tation from the GP presentation study by dividing the number
of consultations due to norovirus in each age group by the per-
son-years of observation in that age group. This was estimated
by multiplying the age-stratiﬁed patient population of each
practice by the time contributed to the study. As above, we com-
puted norovirus-speciﬁc consultation rates as an average from
>20 imputed data sets.
We present incidence rates as cases or consultations per 1000
person-years for the community and for the following age
groups: <1 year, 1–5 years, 5–15 years, 15–64 years, and ≥65
years. For the GP presentation study, the size of the infant
population in each practice was not available, so we present
combined rates for children aged <5 years.
Analysis was performed in Stata 11.0 software (Stata, College
Station, Texas).
Ethics and Consent
A favorable ethical opinion to perform the IID2 study was
granted by the NHS North West Research Ethics Committee
(07/MRE08/5), and all participants gave informed written con-
sent prior to being enrolled in the study.
RESULTS
The overall incidence of norovirus-associated IID in the
community was 47.0 cases per 1000 person-years (95% CI,
39.1–56.5), and 2.1 norovirus-associated IID cases per 1000 per-
son-years (95% CI, 1.4–3) presented to primary healthcare.
Age-speciﬁc norovirus-associated IID incidence rates in
the community were signiﬁcantly higher in children aged <5
years, compared with rates in other age groups (Table 1).
Similarly norovirus-associated IID consultation rates were
much higher in children aged <5 years presenting to primary
healthcare (Table 2). For children aged <5 years, the rate of
norovirus-associated IID in the community was 10 times the
rate associated with primary healthcare consultations. By con-
trast, among older children and adults, there were >30 cases in
the community per primary healthcare consultation; among
those aged ≥65 years, this ratio was 13 cases per primary health-
care consultation.
These results indicate that, among children aged <5 years, ap-
proximately 15% experience norovirus IID each year, and 1.5%
present to primary healthcare for this illness. Uncertainty
around these estimates was high, particularly for the communi-
ty rates, because of the relatively modest number of cases in each
age group.
DISCUSSION
The IID2 study is one of only a handful of population-based
prospective studies globally designed to measure disease inci-
dence by pathogen [1, 7, 8, 13–15], which gives a rare opportu-
nity to estimate age-speciﬁc incidence for norovirus-associated
IID. The incidence estimates of norovirus-associated IID in the
Table 1. Age-Specific Incidence Rates for Norovirus-Associated
Infectious Intestinal Disease in the IID2 Cohort Study
Age Group Cases, No.a Person-Years
Cases/1000 Person-Years,
No. (95% CI)
<1 y 5 26.9 178.2 (70.5–450.0)
1–5 y 26 190.8 137.3 (92.6–203.4)
5–15 y 26 424.1 59.6 (36.8–96.5)
15–64 y 103 2647.8 39.0 (31.3–48.7)
≥65 y 38 1369.1 27.7 (19.6–39.1)
<5 y 31 217.6 142.6 (99.8–203.9)
≥5 y 167 4441.0 37.6 (31.5–44.7)
Abbreviation: CI, confidence interval.
a Cases represent the mean value from 20 imputations.
Table 2. Age-Specific Incidence Rates for Norovirus-Associated
Infectious Intestinal Disease in the IID2 General Practice Presentation
Study
Age Group Cases, No.a Person-Yearsb
Cases/1000 Person-Years,
No. (95% CI)
<5 y 242 16 720.4 14.4 (8.5–24.5)
5–15 y 56 35 211.3 1.5 (.6–4.2)
15–64 y 236 205 597.8 1.1 (.7–1.8)
≥65 y 114 54 702.1 2.1 (1.1–4.0)
<5 y 242 16 720.4 14.4 (8.5–24.5)
≥5 y 406 295 511.2 1.4 (.9–2.0)
Abbreviation: CI, confidence interval.
a Cases represent the mean value from 20 imputations.
b Data for individuals aged <1 year were not available.
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United Kingdom population and presenting to primary health-
care were highest in children aged <5 years.
In a similar study (the IID1 study), in which datawere collected
between 1993 and 1996, the incidence of norovirus-associated IID
in children aged <5 years in the community was 214 cases per
1000 person-years (95% CI, 159–277), and so there had not
been a signiﬁcant change over time, as witnessed by a large over-
lap in CIs [12]. However, the incidence of norovirus-associated
IID in children <5 years of age presenting to primary healthcare
had halved between 1993–1996 (32 cases per 1000 person years;
95% CI, 26–38) and 2008–2009, and this change was statistically
signiﬁcant [12]. In the IID2 study, 15% of children aged <5 years
experienced norovirus-associated IID in a year. The correspond-
ing percentage in the IID1 study was 20% [12].
Given the lack of a population-level intervention, such as vac-
cination, it is not surprising that incidence rates in the 2 popu-
lation-based cohort studies conducted over a decade apart were
similar. What was more surprising was the signiﬁcant decrease
in children with norovirus-associated IID presenting to primary
healthcare. This is unlikely to have been because of a diminu-
tion in the severity of illness. The proportion of people taking
time off work or school because of IID was similar in the 2 stud-
ies, and our hypothesis is that changes to the appointment sys-
tem in primary healthcare services in the United Kingdom in
intervening years, coupled with advice on the NHS Choices
website (available at: http://www.nhs.uk/conditions/norovirus/
pages/treatment.aspx) advising against seeking general practi-
tioner appointments for suspected norovirus, are more likely ex-
planations for the decrease in consultations.
This study had several strengths. The proportion of people
agreeing to take part in the IID2 cohort study was lower than
that in the IID1 study, but this was compensated for by much
better compliance with weekly follow-up [1]. Furthermore, the
number of people lost to follow-up was much lower than that in
the IID1 study [1].
Using molecular methods for pathogen detection meant that
we could investigate low-volume samples, and this decreased
the diagnostic gap among community cases [2]. We used the
same real-time/quantitative RT-PCR assays and the same CT
cutoffs for analyzing the IID1 and IID2 study data, so the chan-
ge in the incidence of norovirus-associated IID presenting to
primary healthcare is likely to be real and not an artifact caused
by using different assays.
The study was limited by the lack of a control group in the
IID2 study, and so, based on previous work, we used a CT
value of <30 as a marker of norovirus-associated IID [12].
Had we used a more sensitive cutoff of <40, which is the stan-
dard in most clinical microbiology laboratories, it is likely that
the age-speciﬁc incidence rates would have been higher. How-
ever, using a more sensitive cutoff would almost certainly have
involved misclassifying asymptomatic excretors as clinical cases
of norovirus-associated IID.
In conclusion, as rotavirus-associated diarrhea comes under
control through vaccination, norovirus-associated IID will as-
sume greater importance. Robust incidence estimates are crucial
for guiding vaccination policy, and this study emphasizes the
impact of norovirus-associated IID across age groups, but espe-
cially in children aged <5 years.
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